Welcome to our dedicated page for Avalon Globocare news (Ticker: ALBT), a resource for investors and traders seeking the latest updates and insights on Avalon Globocare stock.
Avalon GloboCare Corp. reports developments across precision diagnostic consumer products, generative AI publishing and software, and related intellectual property. The company markets the KetoAir breathalyzer device, which is registered with the U.S. Food and Drug Administration as a Class I medical device, and it has described plans to extend breathalyzer technology into additional diagnostic uses.
Recurring company updates also cover Avalon Quantum AI LLC, the Catch-Up generative and agentic AI video platform, provisional patent filings for automated commentary systems, and technology collaborations supporting AI media infrastructure. Avalon news also includes capital-structure actions such as private placements, warrant issuances, debenture conversions, shareholder approvals, and Nasdaq compliance matters.
Avalon GloboCare (NASDAQ: ALBT) announced renewal of the U.S. FDA establishment registration for the KetoAir™ handheld breathalyzer (registration no. 3026284320). KetoAir measures breath acetone concentration (BrAce) using nanosensor technology to provide non-invasive metabolic and ketosis insights for users on ketogenic programs. Avalon plans a combined B2B and B2C launch for KetoAir via Catch-Up™, its generative AI short-form video SaaS, operated by Avalon Quantum AI, LLC. Marketing through Catch-Up™ is planned to begin in the second quarter of 2026 to support distribution, engagement, and adoption across enterprise and consumer channels.
Avalon GloboCare (NASDAQ: ALBT) announced it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement under Rule 5550(b) and is now in compliance with all continued listing standards. The previously scheduled Nasdaq Hearings Panel session was cancelled and Avalon’s common stock will remain listed and traded on Nasdaq.
The company said restoring compliance supports its ability to pursue growth initiatives, including launching marketing for a generative AI video platform and expanding precision diagnostics and strategic assets.
Avalon GloboCare (NASDAQ: ALBT) announced the acquisition of RPM Interactive and highlighted RPM CEO and Avalon board member Michael Mathews discussing RPM’s Catch-Up generative AI video platform in a Dec. 30, 2025 interview.
Catch-Up is described as a SaaS platform that automatically generates recap-style videos using generative AI and large language models, planned for licensing to content creators, media companies and brands across news, sports, finance, entertainment and other categories. Avalon intends to use the platform to support marketing for KetoAir, its FDA-registered breathalyzer for metabolic wellness. The interview is available on ProactiveInvestors.com and on YouTube.
Avalon GloboCare (NASDAQ: ALBT) acquired RPM Interactive in an all-stock merger completed Dec. 12, 2025, effected by merging RPM into newly formed subsidiary Avalon Quantum AI, LLC.
Avalon issued 19,500 shares of Series E preferred (stated value $1,000/share; total purchase price $19.5 million) convertible at $1.50/share subject to a 4.99% ownership cap and conversion restrictions until May 12, 2026 and shareholder approval requirements. The company said this transaction brings stockholders’ equity above the $2.5 million Nasdaq minimum. RPM’s Catch-Up SaaS short-form generative AI video platform will support marketing for KetoAir™ and other consumer products.
Avalon GloboCare (NASDAQ: ALBT) reported Q3 2025 progress for its KetoAir™ breathalyzer, highlighting a UK commercial launch on Sept 1, 2025, presentation at the London Health Optimization Summit on Sept 13–14, 2025, and a Nevada first‑responder program started in August 2025.
The four‑month Nevada POOL/PACT Holistic Health Reset enrolled 50 first responders using KetoAir™ for daily ketone monitoring; October mid‑program data showed individual metabolic improvements. KetoAir™ is FDA‑registered (Reg. No. 3026284320), measures breath acetone (BrAce), and is manufactured by Qi Diagnostics; device apps are available on Apple App Store and Google Play.
Avalon GloboCare (NASDAQ: ALBT) announced the launch of its KetoAir™ breathalyzer device in the United Kingdom, with sales beginning September 1, 2025 through www.KetoAir.uk. The FDA-registered device measures breath acetone concentration to track ketosis and fat metabolism for individuals following ketogenic diets.
The handheld device, manufactured by Qi Diagnostics Limited, features nano-sensor technology and is compatible with both iOS and Android platforms. This UK expansion follows the company's successful U.S. market launch, targeting users pursuing ketogenic lifestyles for weight management, athletic performance, or therapeutic purposes.
[ "Expansion into the UK market broadens geographic footprint", "Product targets growing ketogenic diet market segment", "Device offers cross-platform compatibility (iOS and Android)" ]Avalon GloboCare (NASDAQ: ALBT) has announced a wholesale distribution agreement between its subsidiary Q&A Distribution and Saga Health Corporation for the KetoAir™ breathalyzer device. The device will be integrated into Saga Health's Holistic Health Reset Program targeting first responders.
KetoAir™, registered with the FDA (#3026284320), is a handheld device that measures breath acetone concentration (BrAce) to monitor ketosis and fat metabolism. The device features nano-sensor technology, provides real-time insights, and is compatible with both iOS and Android platforms through dedicated mobile apps.
Avalon GloboCare (NASDAQ: ALBT) has secured a new patent in Hong Kong for its proprietary CAR-T and CAR-Natural Killer (NK) cell technology. The patent (No. HK40074322), co-developed with Arbele Limited, provides 20-year protection effective from February 21, 2020.
The technology features a bispecific Anti-CD19xCD22 CAR design targeting both CD19 and CD22 antigens to reduce tumor escape risk, and a localized cytokine induction system aimed at enhancing immune responses at tumor sites. This patent complements Avalon's existing protections in the United States and other PCT jurisdictions, strengthening their position in cell-based immunotherapy development.
Avalon GloboCare (NASDAQ: ALBT) has entered into a definitive agreement with Qi Diagnostics to co-develop a VOC nanosensor-based cannabis breathalyzer. The collaboration will involve Avalon, its subsidiary Q&A Distribution, and Qi Diagnostics working together to design, validate, and develop a prototype device aimed at detecting potential cannabis-impaired driving in real-time.
The partnership combines Avalon's regulatory expertise with Qi Diagnostics' VOC nanosensor technology to create a non-invasive cannabis detection solution for law enforcement and workplace safety applications.
Avalon GloboCare (NASDAQ: ALBT) has filed a registration statement on Form S-4 with the SEC for its proposed merger with YOOV Group Holding. The merger will be executed through Avalon's subsidiary, Nexus MergerSub, with YOOV becoming a wholly-owned subsidiary of Avalon.
The combined entity will focus on providing Artificial Intelligence-as-a-Service (AIaaS) solutions, specializing in intelligent business automation. The merger aims to create a public company that will help organizations optimize operations, reduce costs, and enhance service delivery through AI technology.
The deal's completion depends on key conditions, including:
- Approval from Avalon stockholders
- Nasdaq Stock Market approval for YOOV listing post-merger